How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Lea Bucher
Advertisement
Lea Bucher is Principal at Executive Insight.
Articles by Lea Bucher
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: FDA Votes 10 to 3 in Favor of Replimune's Rp1 Efficacy Data
2
Why Real-Time Data Analytics Are Vital for the Next Evolution of Clinical Trials
3
Funding Roundup: Braveheart, Attovia, Vogenx All Announce IPO’s
4
M&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquires Vidya Therapeutics, Relation Collaborates with GSK
5